This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

13 Dec 2011

Perifosine in Hodgkin Lymphoma Receives Encouraging Preclinical Data

The encouraging preclinical results underline perifosine's potential in combination therapy with anti-cancer agents.

Aeterna Zentaris Inc. reported Monday encouraging preclinical data for its oral anticancer Akt inhibitor, perifosine, in Hodgkin Lymphoma.


In vitro data from Hodgkin lymphoma (HL) cell lines showed that perifosine combined with sorafenib induced increased apoptosis, while in vivo data for the same combination treatment for HL significantly increased survival in mice.


Data were presented over the weekend by Silvia Locatelli, PhD, Fondazione IRCCS Instituto Nazionale Tumori, Milan, Italy, during the American Society of Hematology (ASH) Annual Meeting and Exposition currently being held in San Diego, California, until December 13, 2011.


Juergen Eng

Related News